• Revenue Cycle Management
  • COVID-19
  • Reimbursement
  • Diabetes Awareness Month
  • Risk Management
  • Patient Retention
  • Staffing
  • Medical Economics® 100th Anniversary
  • Coding and documentation
  • Business of Endocrinology
  • Telehealth
  • Physicians Financial News
  • Cybersecurity
  • Cardiovascular Clinical Consult
  • Locum Tenens, brought to you by LocumLife®
  • Weight Management
  • Business of Women's Health
  • Practice Efficiency
  • Finance and Wealth
  • EHRs
  • Remote Patient Monitoring
  • Sponsored Webinars
  • Medical Technology
  • Billing and collections
  • Acute Pain Management
  • Exclusive Content
  • Value-based Care
  • Business of Pediatrics
  • Concierge Medicine 2.0 by Castle Connolly Private Health Partners
  • Practice Growth
  • Concierge Medicine
  • Business of Cardiology
  • Implementing the Topcon Ocular Telehealth Platform
  • Malpractice
  • Influenza
  • Sexual Health
  • Chronic Conditions
  • Technology
  • Legal and Policy
  • Money
  • Opinion
  • Vaccines
  • Practice Management
  • Patient Relations
  • Careers

Gastric acid drugs may increase hip fracture risk


Use of drugs that inhibit gastric acid is linked to a higher risk of hip fracture among patients, new research shows.

Gastroenterology. 2010;139:93-101. [July 2010]

The use of drugs that inhibit gastric acid is linked to a higher risk of hip fracture among patients; however, with proton pump inhibitors (PPIs) this appears to be limited to those who have at least one other fracture risk factor, according to researchers from the Kaiser Permanente division of research in Oakland, California. The researchers used prescription data to assess the use of PPIs or histamine-2 receptor antagonists (H2RAs) in 33,752 members diagnosed with fractures of the hip/femur, and a matched control group of 130,471 members without fractures for up to 10 years. The researchers found that those who had suffered hip fractures were more likely to have previously received at least a two-year supply of PPIs compared to controls. However, for those who received their last prescription for PPIs 2 to 2.9 years prior, the fracture risk decreased.

Related Videos